Gossamer Bio, Inc. (GOSS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Apr 17, 2026
Current Price
$0.16
Price Target
$0.77
Target Range
$0.30 — $1.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-0.2x
Forward PEG—
Implied Growth+39.9%
Median Target$1.00
Analyst Spread91.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$0
+85.3%
Consensus
$1
+373.6%
Bull Case
$1
+517.7%
GOSS Price Target Analysis
Updated June 13, 2026As of June 13, 2026, Gossamer Bio, Inc. (GOSS) has a Wall Street consensus price target of $0.77, based on estimates from 17 covering analysts. With the stock currently trading at $0.16, this represents a potential upside of +373.6%. The company has a market capitalization of $38M.
Analyst price targets range from a low of $0.30 to a high of $1.00, representing a 91% spread in expectations. The median target of $1.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GOSS trades at a trailing P/E of -0.2x. Analysts expect EPS to grow +39.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+160.1%
Avg Forward P/E23.7x
Peers with Coverage9 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ARWRArrowhead Pharmaceuticals, Inc. | $10.5B | $74.52 | $84.00 | +12.7% | Buy | — | 20 |
 MNKDMannKind Corporation | $1.1B | $3.66 | $8.50 | +132.2% | Buy | — | 19 |
 AVXLAnavex Life Sciences Corp. | $232M | $2.50 | $11.00 | +340.0% | Buy | — | 13 |
 KALAKALA BIO, Inc. | $58M | $2.63 | $18.25 | +593.9% | Buy | — | 9 |
 NKTRNektar Therapeutics | $1.2B | $59.38 | $149.60 | +151.9% | Buy | — | 33 |
 UTHRUnited Therapeutics Corporation | $23.2B | $545.96 | $636.83 | +16.6% | Buy | 19.2x | 30 |
 LGNDLigand Pharmaceuticals Incorporated | $5.1B | $255.54 | $265.33 | +3.8% | Buy | 28.2x | 17 |
 IDYAIDEAYA Biosciences, Inc. | $2.5B | $28.98 | $58.67 | +102.5% | Buy | — | 25 |
 PCVXVaxcyte, Inc. | $6.9B | $47.46 | $89.00 | +87.5% | Buy | — | 11 |
 LUNGPulmonx Corporation | $58M | $1.37 | — | — | — | — | — |
Upside Potential Comparison
KALAAVXLNKTRMNKDIDYAPCVXUTHRARWRWhat if you invested $1,000 in GOSS 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in GOSS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs GOSS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationGOSS vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowGOSS — Frequently Asked Questions
Quick answers to the most common questions about buying GOSS stock.
What is the GOSS stock price target for 2026?
The consensus Wall Street price target for GOSS is $0.7667, representing 373.6% upside from the current price of $0.1619. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is GOSS a buy, sell, or hold?
GOSS has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $0.7667 implies 373.6% upside from current levels.
Is GOSS stock overvalued or undervalued?
GOSS's current price is $0.1619 with a consensus target of $0.7667 (373.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can GOSS stock go?
The most bullish Wall Street analyst has a price target of $1 for GOSS, while the most conservative target is $0.3. The consensus of $0.7667 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover GOSS stock?
GOSS is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 6 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GOSS stock forecast?
The 12-month GOSS stock forecast based on 17 Wall Street analysts shows a consensus price target of $0.7667, with estimates ranging from $0.3 (bear case) to $1 (bull case). The median consensus rating is "Buy".
Should I buy GOSS stock?
Wall Street analysts are very optimistic on GOSS, with a "Buy" consensus rating and $0.7667 price target (373.6% upside). 9 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GOSS price targets vary so much?
GOSS analyst price targets range from $0.3 to $1, a 91% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $0.7667 consensus represents the middle ground.